

Ryah Medtech Inc

15:35 20 Aug 2019

RYAH takes major step towards completion of its reverse takeover of Prime Blockchain

RYAH has made a major step towards the completion of its reverse takeover of Prime Blockchain Inc and its listing on the Canadian Stock Exchange after getting strong support for the deal from Prime shareholders at recent meetings.

In a statement, Prime Blockchain said that at the meetings held on August 19, 2019, in Verdun, Quebec, 15,255,280 ballots were cast in person or by proxy representing 77.81% of the total number of shares issued and outstanding of the company in favour of the transaction.

The resolution for the election of Potbiotics/RYAH directors to the Prime board got even greater backing, with all the names - including RYAH CEO Greg Wagner - receiving 99.9% approval.

At the end of June, the two privately-owned companies signed a binding letter of intent under which Prime Blockchain will acquire the outstanding securities of Potbiotics, RYAH's parent company.

The Quebec-based company plans to change its name to RYAH as well as replacing its directors with RYAH's nominees...

Potbiotics, which operates as RYAH, is a New York-based company that brings big data to dry herb medicine. Its RYAH MediTech business produces a signature vaporizer that can precisely track dose and temperature and pairs with an app that uses artificial intelligence to help patients identify what treatments work best for them.

Prime and RYAH are jointly preparing a listing statement so their shares can apply for listing on the CSE, and the firms said that as this file advances RYAH and Prime will issue news releases outlining the progress.

Contact the author at jon.hopkins@proactiveinvestors.com

Share Information

Code: RYAH
Listing: PRIVATE-NA
Sector: Cannabis
Website: us.ryah.com

Company Synopsis:

*RYAH is the first vaporizer that lets users track and control how much they inhale, ensuring consistent, predictable results. It offers accurate temperature and dosing control down to the millileter. *

*The device tracks the effects of each session and uses artificial intelligence to help select the best strain of cannabis for any patient's symptoms. *

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Ryah Medtech Inc named herein, including the promotion by the Company of Ryah Medtech Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).